JP2023518430A5 - - Google Patents

Info

Publication number
JP2023518430A5
JP2023518430A5 JP2022556099A JP2022556099A JP2023518430A5 JP 2023518430 A5 JP2023518430 A5 JP 2023518430A5 JP 2022556099 A JP2022556099 A JP 2022556099A JP 2022556099 A JP2022556099 A JP 2022556099A JP 2023518430 A5 JP2023518430 A5 JP 2023518430A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
therapeutically effective
effective dose
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050350 external-priority patent/WO2021184115A1/en
Publication of JP2023518430A publication Critical patent/JP2023518430A/ja
Publication of JP2023518430A5 publication Critical patent/JP2023518430A5/ja
Pending legal-status Critical Current

Links

JP2022556099A 2020-03-19 2021-03-16 感染症の治療におけるブシラミンの使用 Pending JP2023518430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991996P 2020-03-19 2020-03-19
US62/991,996 2020-03-19
PCT/CA2021/050350 WO2021184115A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases

Publications (2)

Publication Number Publication Date
JP2023518430A JP2023518430A (ja) 2023-05-01
JP2023518430A5 true JP2023518430A5 (https=) 2024-02-02

Family

ID=77767915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556099A Pending JP2023518430A (ja) 2020-03-19 2021-03-16 感染症の治療におけるブシラミンの使用

Country Status (5)

Country Link
US (1) US20230172884A1 (https=)
EP (1) EP4121035A4 (https=)
JP (1) JP2023518430A (https=)
KR (1) KR20230015320A (https=)
WO (1) WO2021184115A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183146A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
WO2011094598A2 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9238018B2 (en) * 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
CA3017797A1 (en) * 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Similar Documents

Publication Publication Date Title
JP2023503309A5 (https=)
JP2022058688A5 (https=)
JP2023503303A5 (https=)
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP2023503068A5 (https=)
JP2023503071A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2024540183A5 (https=)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2018507914A5 (https=)
JP2014515373A5 (https=)
JP2005516904A5 (https=)
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
JP2018531273A5 (https=)
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
JP2023518430A5 (https=)
CN101654393A (zh) 作为肝脏保护剂的化合物和组合物
JP2019507786A5 (https=)
JP2024528731A5 (https=)
JP2022517902A5 (https=)
JP2021512086A5 (https=)
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
JP2008533079A5 (https=)